For research use only. Not for therapeutic Use.
BMS-986325 (Cat No.: I040030) is an investigational monoclonal antibody targeting CD40, a costimulatory receptor expressed on antigen-presenting cells such as dendritic cells, B cells, and macrophages. By modulating CD40 signaling, it enhances immune activation, promoting T-cell-mediated anti-tumor responses. Developed by Bristol Myers Squibb, BMS-986325 is being studied as an immuno-oncology therapeutic, potentially in combination with checkpoint inhibitors or cancer vaccines. Its selective targeting of CD40 aims to boost anti-tumor immunity while minimizing systemic immune-related toxicity, making it a promising candidate in cancer immunotherapy research.
| Purity | ≥95% |
| Reference | [1]. Aaron YAMNIUKA, et al. ntagonistic cd40 monoclonal antibodies and uses thereof. Patent. WO2020106620A1 |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
.gif)